POAG & PACG optic disc topography similar

Article

When the amount of optic nerve damage is taken into account, there is little difference in the optic disc topography of patients with primary open-angle glaucoma (POAG) and those with primary angle-closure glaucoma.

When the amount of optic nerve damage is taken into account, there is little difference in the optic disc topography of patients with primary open-angle glaucoma (POAG) and those with primary angle-closure glaucoma (PACG), according to a study published in the February issue of Ophthalmology.

Michael Boland and colleagues from the Wilmer Eye Institute, John Hopkins University, Maryland, USA carried out an observational case study to compare the optic disc and visual field (VF) alterations in POAG and PACG. A total of 110 POAG patients and 36 PACG patients were enrolled.

Each subject underwent visual acuity (VA) measurements, applanation tonometry, gonioscopy, slit-lamp examination, dilated optic disc and retinal examination, axial length measurement, central corneal pachymetry, automated perimetry, optical coherence tomography (OCT) nerve fibre layer (NFL) examination and Heidelberg Retina Tomograph (HRT) optic disc evaluation.

The results demonstrated that the VF average mean deviation (MD) did not significantly differ between POAG and PACG but the PACG group had lower pattern standard deviation (PSD) for a given MD (p=0.001). Although three HRT parameters differed somewhat between the two groups (cup area, rim area and cup-to-disc area ratio), they did not significantly differ after correction for multiple comparisons. MD and disc area were much more significant predictors of the HRT measures than was diagnosis. When controlling for MD, current intraocular pressure was not significantly associated with disc parameters in POAG.

It was concluded that, when the amount of optic nerve damage is taken into account, there is little difference in the optic disc topography of patients with POAG and those with PACG.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.